country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-190426

Copy Link Print Information

IAV-IN-6

IAV-IN-6 is an influenza A virus (IAV) inhibitor. IAV-IN-6 exhibits broad-spectrum antiviral activity against HPIV3, EV-D68, RVFV, and VEEV.

For research use only. We do not sell to patients.

Formula: C₂₄H₂₅NO₃S₂
Molecular Weight:439.59

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

IAV-IN-6 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IAV-IN-6 is an influenza A virus (IAV) inhibitor. IAV-IN-6 exhibits broad-spectrum antiviral activity against HPIV3, EV-D68, RVFV, and VEEV^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC50	21.25 μM	Inhibition of influenza A/(H1N1)pdm09 infection in human lung carcinoma epithelial A549 cells assessed by immunofluorescence-based focus assay after 16 hrs. Inhibition of influenza A/(H1N1)pdm09 infection in human lung carcinoma epithelial A549 cells assessed by immunofluorescence-based focus assay after 16 hrs.	42858569
A549	CC₅₀	>400 μM	Cytotoxicity against human lung carcinoma epithelial A549 cells assessed as viability by CellTiter-Glo luminescent assay after 24 hrs, CC₅₀ >400 μM. Cytotoxicity against human lung carcinoma epithelial A549 cells assessed as viability by CellTiter-Glo luminescent assay after 24 hrs, CC₅₀ >400 μM.	42858569
A549	IC50	14.6 μM	Inhibition of HPIV3-GFP infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression. Inhibition of HPIV3-GFP infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression.	42858569
A549	IC50	13.5 μM	Inhibition of EV-D68 infection in A549 cells by cell-based antiviral infectivity assay assessed by immunofluorescence using anti-enterovirus VP3 antibody. Inhibition of EV-D68 infection in A549 cells by cell-based antiviral infectivity assay assessed by immunofluorescence using anti-enterovirus VP3 antibody.	42858569
A549	IC50	27.5 μM	Inhibition of rRVFVΔNSsKatushka infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression. Inhibition of rRVFVΔNSsKatushka infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression.	42858569
A549	IC50	18.6 μM	Inhibition of VEEV-GFP infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression. Inhibition of VEEV-GFP infection in A549 cells by cell-based antiviral infectivity assay assessed as reporter protein expression.	42858569

In Vitro

Viral InfectionOthers

Viral Infection

IAV-IN-6 (Compound 35D) (0.39-100 µM; 16 h) inhibits influenza A/(H1N1) pdm09 infection in A549 cells with an IC₅₀ of 21.25 µM^[1].
IAV-IN-6 (25 µM; 48 h) reverses IAV-H1N1pdm09-induced CPE in A549 cells^[1].
IAV-IN-6 (50 µM; −2-24 h) interferes with the early post-attachment stage of the IAV-H1N1pdm09 life cycle in A549 cells without affecting replication, assembly, or release^[1].
IAV-IN-6 exhibits broad-spectrum antiviral activity against HPIV3, EV-D68, RVFV, and VEEV, with IC₅₀ values of 14.6, 13.5, 27.5, and 18.6 µM^[1], respectively.

Others

IAV-IN-6 (1.562-400 µM; 24 h) shows minimal cytotoxicity in A549 cells, with CC₅₀ >400 µM and SI >18.82^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

A549 cells
Concentration:

0.39-100 µM
Incubation Time:

16 h
Result:

Inhibited IAV-H1N1pdm09 infection with IC₅₀ = 21.25 µM.

Cell Viability Assay^[1]

Cell Line:

A549 cells
Concentration:

1.562-400 µM
Incubation Time:

24 h
Result:

CC₅₀ >400 µM in A549 cells; SI >18.82.

Immunofluorescence^[1]

Cell Line:

A549 cells
Concentration:

50 µM
Incubation Time:

−2-0, 0-2, 2-4, 4-6, 6-8, 8-10, and 10-24 h; 24 h post-infection
Result:

Virus infection was significantly reduced only when added during the adsorption stage (0-2 h).
No antiviral activity was observed when added at any other time point.

Related Protocols :

Research Protocol for Infectious Diseases

Chemical Information

Molecular Weight 439.59
Formula C₂₄H₂₅NO₃S₂
SMILES

O=C1C=C(CC2=CC=C(C(C)(C)C)C=C2)C(C3=CC=CS3)=C4N1C(CC(O)=O)CS4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Nyantakyi SA, et al. Discovery of dihydrothiazolo ring-fused 2-pyridones with extended carboxylic acid as anti-influenza A agents. European journal of medicinal chemistry. 2026 Oct 05;321(Pt 1):119397.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote